Tolerability, Pharmacokinetics, and Serum Bactericidal Activity of Intravenous Dalbavancin in Healthy Volunteers

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 3, 2004, Pages 940-945

  Leighton, Anton ^a   Gottlieb, Alice Bendix ^c   Dorr, Mary Beth ^a   Jabes, Daniela ^a,b   Mosconi, Giorgio ^b   VanSaders, Claudia ^c   Mroszczak, Edward J ^a   Campbell, Kathleen C M ^d   Kelly, Ellen ^e  

^a Vicuron Pharmaceuticals   (United States)

^b Vicuron Pharmaceuticals   (Italy)

^c ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^d SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Center for Speech and Hearing Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DALBAVANCIN; PLACEBO;

ADULT; AREA UNDER THE CURVE; ARTICLE; BACTERICIDAL ACTIVITY; BLISTER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EXCRETION; DRUG HALF LIFE; DRUG LOADING DOSE; DRUG TISSUE LEVEL; DRUG TOLERABILITY; DRUG URINE LEVEL; FEMALE; FEVER; HEADACHE; HEARING; HUMAN; HYPERGLYCEMIA; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; MAINTENANCE DRUG DOSE; MALE; MAXIMUM TOLERATED DOSE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTIPLE DRUG DOSE; NAUSEA; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; URINARY EXCRETION; VESTIBULAR FUNCTION;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; DOUBLE-BLIND METHOD; FEMALE; GLYCOPEPTIDES; HALF-LIFE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; SERUM BACTERICIDAL TEST; STAPHYLOCOCCUS AUREUS; TEICOPLANIN;

EID: 1442349121     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.3.940-945.2004     Document Type: Article

References (14)

1. American Speech-Language Hearing Association. 1994. Guidelines for the audiologic management of individuals receiving cochleotoxic drug therapy. Am. Speech-Lang. Hear. Assoc. 36:11-19.
2. Campbell, K. C. M., E. Kelly, and N. Targovnik, L. Hughes, C. Van Saders, A. B. Gottlieb, M. B. Dorr, and A. Leighton. 2003. Audiologic monitoring for potential ototoxicity in a phase 1 clinical trial of a new glycopeptide antibiotic. J. Am. Acad. Audiol. 14:157-168.
3. Candiani, G., M. Abbondi, M. Borgonovi, G. Romanò, and F. Parenti. 1999. In vitro and in vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibiotic. J. Antimicrob. Chemother. 44:179-192.
4. Diekema, D. J., M. A. Pfaller, R. N. Jones, G. V. Doern, K. C. Kuegler, M. L. Beach, H. S. Sader, and The SENTRY Participants Group. 2002. Trends in antimicrobial susceptibility of bacterial pathogens isolated from patients with bloodstream infections in the USA, Canada and Latin America: report from the SENTRY Antimicrobial Surveillance Programme, 1998. Int. J. Antimicrob. Agents 13:257-271.
5. Goldstein, E. J. C., D. M. Citron, C. V. Merriam, U. Warren, K. Tyrell, and H. T. Fernandez. 2003. In vitro activities of dalbavancin and nine comparator agents against anaerobic gram-positive species and corynebacteria. Antimicrob. Agents Chemother. 47:1968-1971.
6. Jabes, D., G. Candiani, G. Romanò, C. Brunati, S. Riva, and M. Cavaleri. Antimicrob. Agents Chemother., in press.
7. Jones, R. N., D. J. Biedenbach, D. M. Johnson, and M. A. Pfaller. 2001. In vitro evaluation of BI 397, a novel glycopeptide antimicrobial agent. J. Chemother. 13:244-254.
8. Malabarba, A., and S. Donadio. 1999. BI 397, glycopeptide antibiotics. Drugs Future 24:839-846.
9. Maranan, M. C., B. Moreira, S. Boyle-Vavra, and R. S. Daum. 1997. Antimicrobial resistance in Staphylococci: epidemiology, molecular mechanisms, and clinical relevance. Infect. Dis. Clin. N. Am. 11:813-849.
10. National Committee for Clinical Laboratory Standards. 1999. Methodology for the serum bactericidal test. Approved standard M21-A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
11. Ratain, M. J., R. Mick, R. L. Schilsky, R. L. Siegler, and M. Siegler. 1993. Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents. J. Natl. Cancer Inst. 85:1637-1643.
12. Streit, J. M., T. R. Fritsche, H. S. Sader, and R. N. Jones. Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates. Diagn. Microbiol. Infect. Dis., in press.
13. Voss, A., D. Milatovic, and C. Wallrauch-Schwarz, V. T. Rosdahl, and I. Braveny. 1994. Methicillin-resistant Staphylococcus aureus in Europe. Eur. J. Clin. Microbiol. Infect. Dis. 13:50-55.
14. Wilson, A. P. 2000. Clinical pharmacokinetics of teicoplanin. Clin. Pharmacokinet. 39:167-183.